Clinical Trial Update: Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma. [Phase 2]

View source ↗

Summary

Phase 2 trial of anlotinib combined with niraparib for platinum-resistant recurrent clear cell ovarian cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Platinum-resistant Recurrent Clear Cell Ovarian Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Niraparib (Niraparib)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Platinum-resistant Recurrent Clear Cell Ovarian Cancer | Phase 2 | Status: COMPLETED